BCMA-CD19 Dual-Targeted CAR-T Cell Therapy for Relapsed or Refractory AL Amyloidosis - PubMed
3 hours ago
- #AL amyloidosis
- #CAR-T therapy
- #clinical trial
- BCMA-CD19 dual-targeted CAR-T cell therapy shows efficacy and safety in relapsed/refractory AL amyloidosis patients.
- All 6 enrolled patients achieved hematological complete response (100%) and renal response (100%).
- Median time to hematological response was 9 days, and renal response was 75 days.
- One patient relapsed at month 6; others remained in remission. Side effects included mild cytokine release syndrome, pneumonia, urticaria, and acute kidney injury.
- Single-cell sequencing confirmed clearance of pathogenic plasma cells and B cells, promoting immune reconstitution.